Forward PE Ratio: 24.29
The forward PE ratio is 24.29 as of Thursday, July 9, 2026.
Forward PE Ratio (24.29) = Close Price ($158.29) / Consensus Forward EPS ($6.48)
PODD Forward PE Ratio Metrics
FORWARD PE RATIO
24.29
PODD Competitors' Forward PE Ratio
Insulet Corp.
Market Cap
$10.96B
Forward PE Ratio
24.29
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Insulet Corp. (PODD) | $10.96B | 24.29 |
| Bio-Techne Corporation (TECH)vs › | $11.14B | 36.89 |
| Tempus AI, Inc. (TEM)vs › | $10.73B | N/A |
| Charles River Laboratories International, Inc. (CRL)vs › | $11.25B | 20.18 |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | 7.65 |
| Baxter International Inc. (BAX)vs › | $11.60B | 11.45 |
| Molina Healthcare, Inc. (MOH)vs › | $12.09B | 45.00 |
| Universal Health Services, Inc. (UHS)vs › | $9.72B | 6.66 |
| Henry Schein, Inc. (HSIC)vs › | $9.55B | 15.56 |
| Revvity, Inc. (RVTY)vs › | $12.60B | 20.86 |
Trailing vs Forward
Trailing P/E
36.6
reported TTM EPS
Forward P/E
24.3
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $6.48 implies +50.7% EPS growth vs the reported trailing $4.30.
Forward P/E by Fiscal Year
View All Analyst EstimatesAt today's $158.29 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $6.48 | $6.39 – $6.58 | 13 | 24.4x |
| 2027-12-31 | $8.08 | $7.43 – $8.42 | 14 | 19.6x |
| 2028-12-31 | $10.15 | $9.55 – $10.48 | 7 | 15.6x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
Forward PE Ratio Formula & Definition
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Forward PE Ratio FAQ
- What is the forward PE ratio for Insulet Corp. (PODD)?
- The forward PE ratio for PODD stock is 24.29.
Related Metrics
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley McEvoy